Duggan, Andy, Warner, Juliet, Knapp, Martin 
ORCID: 0000-0003-1427-0215 and Kerwin, Robert
(2003)
Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.
British Journal of Psychiatry, 182 (6).
pp. 505-508.
ISSN 0007-1250
Abstract
Background: Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors. Clozapine reduces symptoms in 60% of such patients and significantly decreases the risk of suicide. Aims: To model the impact of increased clozapine prescribing on lives saved and resource utilisation. Method: A model was built to compare current levels of clozapine prescribing with a scenario in which all suitable patients with treatment-resistant schizophrenia received clozapine. Results: It was estimated that an average of 53 lives could be saved in the UK each year. If clozapine is cost-neutral, the cost per life-year saved is £5108. If clozapine achieves a 10% reduction in annual support costs, the net saving is £8.7 million per annum. An average of 167 acute beds would be freed each year. Conclusions: The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective.
| Item Type: | Article |
|---|---|
| Official URL: | http://bjp.rcpsych.org |
| Additional Information: | © 2003 Royal College of Psychiatrists |
| Divisions: | Social Policy Care Policy and Evaluation Centre LSE Health |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
| Date Deposited: | 05 Sep 2008 13:41 |
| Last Modified: | 01 Nov 2024 04:17 |
| URI: | http://eprints.lse.ac.uk/id/eprint/18120 |
Actions (login required)
 |
View Item |
